While the Ministry of Health’s (MOH) announcement in Parliament today that the National Health Fund (DKN) Act is targeted for 2029 is a welcome long-term reform under the 13th Malaysia Plan, critically ill Malaysians cannot afford to wait another three years for access to life-saving treatment.

Innovative Medicines: Addressing Funding Gaps And Access Delays

For patients requiring targeted therapies in areas such as chronic diseases, haematology, and oncology, access is often constrained by limited funding and lengthy approval and reimbursement processes.

Public spending on innovative medicines remains low compared with many upper-middle-income countries, while out-of-pocket health care spending continues to account for around 36 to 37 per cent of total health expenditure.